Compare KEEL & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KEEL | KARD |
|---|---|---|
| Founded | 2017 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2020 | 2026 |
| Metric | KEEL | KARD |
|---|---|---|
| Price | $3.42 | $14.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $6.55 | ★ $42.25 |
| AVG Volume (30 Days) | ★ 25.0M | 500.6K |
| Earning Date | 11-12-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $229,276,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 72.03 | N/A |
| 52 Week Low | $2.96 | $13.75 |
| 52 Week High | $7.37 | $27.00 |
| Indicator | KEEL | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 32.59 |
| Support Level | $3.09 | $13.75 |
| Resistance Level | $3.91 | $22.81 |
| Average True Range (ATR) | 0.21 | 1.22 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 24.75 | 21.59 |
Keel Infrastructure Corp is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including AI. The group has a pipeline of 2.2 gigawatts and established grid interconnections already in place. It delivers scalable infrastructure solutions in high-demand power markets across Pennsylvania and Washington in the United States, and Quebec in Canada. It has data campuses in Moses Lake, Panther Creek, Sharon, Sherbrooke, and Scrubgrass.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.